Mylan Specialty
CompanyUnited States
Mylan Specialty develops one asset, in phase 2, discontinued (silibinin in amanita poisoning). Mostly small molecule; based in the United States.
- 1
- Asset
- Furthest stage
- Phase 2, discontinued
- 1
- Trial
- 4
- Signals
Pipeline
1Inhibits hepatitis C virus replication and entry into liver cells.
Phase 2, discontinued, Small molecule, amanita poisoning, amatoxin poisoning
Full company profiles: pipeline, trials, funding and people.
In the full profile
- Evidence behind the mechanisms1
- Trials3
- Signals6
- Similar companies6